Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase IIa Study of JAB-8263 in Patients With Active Rheumatoid Arthritis
Sponsor: Jacobio Pharmaceuticals Co., Ltd.
Summary
This study is an open-label, multi-center Phase IIa study. The study is divided into two phases. The first phase is a safety exploration phase. Participants with active rheumatoid arthritis were enrolled and treated with JAB-8263 alone for 4 weeks. The purpose is to evaluate the safety, PK/PD characteristics and preliminary effectiveness of JAB-8263 in participants with active RA.
Official title: A Phase IIa Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JAB-8263 in Patients With Active Rheumatoid Arthritis
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
32
Start Date
2026-07-23
Completion Date
2027-12-31
Last Updated
2026-09-28
Healthy Volunteers
No
Conditions
Interventions
JAB-8263
Variable dose1, orally Q2D with 28 days
JAB-8263
Variable dose2, orally Q2D with 28 days
Locations (1)
Beijing Hospital
Beijing, Beijing Municipality, China